Clinical Trial

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Name: Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE — clinical trial record (NCT07331467)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Record status

This record was last updated January 12, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Summary

This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.

Trial Details

NCT Number	NCT07331467
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Systemic Lupus Erythematosus
Enrollment	18 participants
Start Date	2026-01
Primary Completion	2026-07 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-01-12